Interrogating Local Recurrence Biology in Rectal Cancer Employing Bulk Gene Expression Profiling

BACKGROUND: Despite modern multimodal therapy for rectal cancer, up to 10% develop local recurrence. Current risk factors do not consider tumor biology, are confined to clinical staging criteria, but form the basis for neoadjuvant therapy decisions. OBJECTIVE: To interrogate biological pathways and traits across 1. primary rectal cancer cured by surgery; 2. primary rectal cancer that recurred following surgery; and 3. locally recurrent rectal cancer. DESIGN: Full tumor sections from a resectional tumor cohort were macrodissected before RNA extraction and bulk Illumina Nova-seq sequencing. Pairwise gene set enrichment analyses, microenvironment cell population deconvolution (MCPCounter) and colorectal cancer Consensus-Molecular-Subtype subtyping were performed. SETTINGS: Two UK centers. PATIENTS: Patients undergoing resectional surgery for primary and locally recurrent rectal cancer with available archival tissue MAIN OUTCOME MEASURES: Biological signatures derived from bulk transcriptomic analysis of tumors. RESULTS: One hundred two tumors were eligible for analysis (28 cured primary rectal cancers, 38 primary rectal cancer that recurred and 36 locally recurrent rectal cancer). Primary rectal cancer that recurred had the highest proportion of neoadjuvant treatment, involved surgical margins, low height and poor differentiation (all p < 0.05). The Top 3 enriched pathways in primary rectal cancer that recurred vs. cured primary rectal cancers were “myogenesis”, “epithelial-mesenchymal transition” and “ KRAS signaling dn” pathways. The Top 3 enriched pathways in locally recurrent rectal cancer vs. primary rectal cancer that recurred & cured primary rectal cancers were “epithelial-mesenchymal transition”, “myogenesis” and hypoxia. The Top 3 down-regulated pathways in both Primary rectal cancer that recurred vs cured primary rectal cancers and locally recurrent rectal cancer vs primary rectal cancer that recurred & cured primary rectal cancers were consistent: “ MYC targets V1”, “E2F targets” and “G2M checkpoint”. In MCPCounter analysis, locally recurrent rectal cancer and primary rectal cancer that recurred relate to lower B-cell and T-cell as well as higher fibroblast, endothelial, neutrophil and monocyte populations (all p < 0.05). Locally recurrent rectal cancer and primary rectal cancer that recurred were most commonly Consensus-Molecular-Subtype-4 tumors, (54.2 and 45.8%, respectively) while cured primary rectal cancers was most commonly Consensus-Molecular-Subtype-2 (54.2%). LIMITATIONS: Modest sized cohort. Risk of confounding bias between groups. CONCLUSIONS: Locally recurrent rectal cancer is associated with stereotypical high-risk biological pathways, dysregulated adaptive immune responses and fibroblast enrichment. These features are present in primary tumors, suggesting potential to develop future early locally recurrent rectal cancer biomarkers.

Authors

Institutions

Publication Details

Journal
Diseases of the Colon & Rectum
Published
2026-11-19
DOI
https://doi.org/10.1097/dcr.0000000000004540
Primary Topic
Colorectal Cancer Surgical Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Interrogating Local Recurrence Biology in Rectal Cancer Employing Bulk Gene Expression Profiling

Guang‐Yu Lian, Alison Wallace, Tom A. Wright, Ross K. McMahon et al.
Diseases of the Colon & Rectum
Colorectal Cancer Surgical Treatments
article

Interrogating Local Recurrence Biology in Rectal Cancer Employing Bulk Gene Expression Profiling

Guang‐Yu Lian, Alison Wallace, Tom A. Wright, Ross K. McMahon, Laura E. Gould, Paul G. Horgan, Campbell S.D. Roxburgh, Joanne Edwards, A McCulloch, Dr philip dunne, Chia Yew Kong, Colin W Steele, Norman Galbraith, Noori Maka, Peter Chong, Lily V.S. Hillson, John Jenkins, Martha Quinn
article en

Abstract

BACKGROUND: Despite modern multimodal therapy for rectal cancer, up to 10% develop local recurrence. Current risk factors do not consider tumor biology, are confined to clinical staging criteria, but form the basis for neoadjuvant therapy decisions. OBJECTIVE: To interrogate biological pathways and traits across 1. primary rectal cancer cured by surgery; 2. primary rectal cancer that recurred following surgery; and 3. locally recurrent rectal cancer. DESIGN: Full tumor sections from a resectional tumor cohort were macrodissected before RNA extraction and bulk Illumina Nova-seq sequencing. Pairwise gene set enrichment analyses, microenvironment cell population deconvolution (MCPCounter) and colorectal cancer Consensus-Molecular-Subtype subtyping were performed. SETTINGS: Two UK centers. PATIENTS: Patients undergoing resectional surgery for primary and locally recurrent rectal cancer with available archival tissue MAIN OUTCOME MEASURES: Biological signatures derived from bulk transcriptomic analysis of tumors. RESULTS: One hundred two tumors were eligible for analysis (28 cured primary rectal cancers, 38 primary rectal cancer that recurred and 36 locally recurrent rectal cancer). Primary rectal cancer that recurred had the highest proportion of neoadjuvant treatment, involved surgical margins, low height and poor differentiation (all p < 0.05). The Top 3 enriched pathways in primary rectal cancer that recurred vs. cured primary rectal cancers were “myogenesis”, “epithelial-mesenchymal transition” and “ KRAS signaling dn” pathways. The Top 3 enriched pathways in locally recurrent rectal cancer vs. primary rectal cancer that recurred & cured primary rectal cancers were “epithelial-mesenchymal transition”, “myogenesis” and hypoxia. The Top 3 down-regulated pathways in both Primary rectal cancer that recurred vs cured primary rectal cancers and locally recurrent rectal cancer vs primary rectal cancer that recurred & cured primary rectal cancers were consistent: “ MYC targets V1”, “E2F targets” and “G2M checkpoint”. In MCPCounter analysis, locally recurrent rectal cancer and primary rectal cancer that recurred relate to lower B-cell and T-cell as well as higher fibroblast, endothelial, neutrophil and monocyte populations (all p < 0.05). Locally recurrent rectal cancer and primary rectal cancer that recurred were most commonly Consensus-Molecular-Subtype-4 tumors, (54.2 and 45.8%, respectively) while cured primary rectal cancers was most commonly Consensus-Molecular-Subtype-2 (54.2%). LIMITATIONS: Modest sized cohort. Risk of confounding bias between groups. CONCLUSIONS: Locally recurrent rectal cancer is associated with stereotypical high-risk biological pathways, dysregulated adaptive immune responses and fibroblast enrichment. These features are present in primary tumors, suggesting potential to develop future early locally recurrent rectal cancer biomarkers.

Diseases of the Colon & Rectum
Queen's University Belfast (GB), Glasgow Royal Infirmary (GB), Queen Elizabeth University Hospital (GB), St Mark's Hospital (GB), University of Glasgow (GB)
Good health and well-being
Colorectal Cancer Surgical Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon